The company said it is resuming enrollment in the AVANT GUARD clinical trial as of November 7, 2024. The trial studies a new population of drug-naïve patients with persistent atrial fibrillation.

1. 01

   The company said it is resuming enrollment in the AVANT GUARD clinical trial as of November 7, 2024. The trial studies a new population of drug-naïve patients with persistent atrial fibrillation.

2. 02

   The company said the decision to resume enrollment was made after an assessment of observations within the trial, in conjunction with the study's data monitoring committee.

3. 03

   The company said the information in Item 7.01 is not deemed filed under the Securities Exchange Act of 1934, Section 18, and is not deemed incorporated by reference into filings under the Securities Act or the Exchange Act.

4. 04

   The company filed the Form 8-K on November 7, 2024, and the report was signed by Susan Thompson, Vice President, Chief Corporate Counsel and Assistant Secretary.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.